Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 18/20 | 0.64 |
| ▸ | SMARCA2 | P51531 | 16/20 | 0.64 |
| ▸ | SMARCA4 | P51532 | 16/20 | 0.64 |
| ▸ | NR1I2 | O75469 | 9/20 | 0.55 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21421571 | 0.86 | PBRM1 (0.78) | PBRM1SMARCA2SMARCA4NR1I2NR1H2 | |
| SCHEMBL23204869 | 0.85 | PBRM1 (0.56) | PBRM1SMARCA2SMARCA4NR1I2NR1H2 | |
| SCHEMBL18081213 | 0.84 | PBRM1 (0.69) | PBRM1SMARCA2SMARCA4NR1I2NR1H2 | |
| SCHEMBL21673513 | 0.82 | PBRM1 (0.61) | PBRM1SMARCA2SMARCA4NR1I2NR1H2 | |
| SCHEMBL25610665 | 0.81 | PBRM1 (0.56) | PBRM1SMARCA2SMARCA4NR1I2NR1H2 | |
| SCHEMBL21421686 | 0.81 | PBRM1 (0.72) | PBRM1SMARCA2SMARCA4NR1I2NR1H2 | |
| SCHEMBL23205540 | 0.80 | SMARCA2 (0.60) | PBRM1SMARCA2SMARCA4NR1I2NR1H2 | |
| SCHEMBL21421572 | 0.80 | PBRM1 (0.71) | PBRM1SMARCA2SMARCA4NR1I2NR1H2 | |
| SCHEMBL21456006 | 0.79 | PBRM1 (0.70) | PBRM1SMARCA2SMARCA4NR1I2NR1H2 | |
| SCHEMBL18038799 | 0.79 | PBRM1 (1.00) | PBRM1SMARCA2SMARCA4NR1I2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230112485-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| WO-2023018648-A1 | PHENOL DERIVATIVES FOR USE IN THE MODULATION OF BRM | GENENTECH, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2021067606-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20200038378-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | GENENTECH, INC. | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230112485-A1 | THERAPEUTIC COMPOUNDS | BRDT, BRPF3, SNRPE | PBRM1 57/4885SMARCA2 26/4885SMARCA4 27/4885 |
| US-20200038378-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, BRAP, VHL | PBRM1 18/4885SMARCA2 23/4885SMARCA4 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.